Latest Strategy Changes News

Australis Oil & Gas reported a $24.9 million loss in 2025, driven largely by impairment charges linked to strategic asset transactions. The company secured a major development partner and sold a significant stake in producing wells, enabling full debt repayment and bolstering cash reserves.

US Masters Residential Property Group reported a $57.3 million net loss for 2025 amid a strategic shift to wind down operations by selling its entire US residential property portfolio by the end of 2026. The Group surpassed its aggressive 2025 sales target, setting the stage for capital returns to security holders.

BluGlass Limited reported a 14% revenue increase to A$5.76 million and a 28% reduction in net loss to A$4.1 million for H1 FY26, bolstered by a key US Department of War contract extension and a refreshed board driving growth.

CVC Limited has finalized the unconditional sale of its Laverton property through a joint venture, forecasting a significant profit and strong cash inflow for FY 2026.

Australian Dairy Nutritionals Group has cut its net loss by 40% in the half-year to December 2025, driven by a remarkable 431% revenue jump in its nutritional powders segment amid expanding Chinese distribution.

MCS Services Limited has finalized a revised agreement to sell the core assets of its subsidiary Highways Traffic Pty Ltd to Altus Traffic for $1.16 million, pending shareholder approval. This marks a strategic step in MCS’s ongoing business realignment following the sale of its larger security division.

Pilot Energy is advancing Australia’s first Direct Air Capture demonstration facility at its Cliff Head site, aiming to start operations by mid-2026 and pave the way for a large-scale carbon removal plant.

NOVONIX Limited posted a $92.7 million net loss for 2025 while progressing its synthetic graphite anode materials business and preparing to divest its Battery Technology Solutions segment.

Advanced Braking Technology Ltd has corrected its half-year results to reveal a robust 55.2% increase in earnings per share, alongside a strong 27% revenue growth driven by demand for its safety braking systems.

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Desane Group Holdings reports a modest half-year profit with stable assets and gearing, completes a key property sale, and pushes forward with a major industrial development in Penrith.